Back Our latest news News selection Discover below our latest news and publications related to our oncology compounds and antibiotics. Press releases April 30, 2024 Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1… Read more April 4, 2024 Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego Read more March 7, 2024 Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors Read more All Press Releases Publications May 1, 2024 First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma Read more April 28, 2024 Gofabicin – A new FabI-inhibitor targeting antibiotic-resistant Neisseria gonorrhoeae Read more April 8, 2024 Anti-Tumor Activity of Debio 0123 in Combination with Sacituzumab Govitecan in Preclinical Models of Breast Cancer Read more All Publications About us Partnering with us Product focus Digital Health Our latest news Pipeline